<?xml version="1.0" encoding="UTF-8"?>
<p>Cholesterol‐25‐hydroxylase (CH25H) is one of the ISGs (Schneider 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0026" ref-type="ref">2014</xref>), which encodes an enzyme that synthesizes the oxysterol 25‐hydroxycholesterol (25HC) from cholesterol (Lund 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0020" ref-type="ref">1998</xref>). 25HC has been shown to have broad antiviral activity by inhibiting the host cell entry of human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), Zika virus (ZIKV), Ebola virus (EBOV), Nipah virus (NiV), Russian spring‐summer encephalitis virus (RSSEV), porcine viruses (PEDV, PEGV, porcine intestine coronavirus), reovirus, and norovirus (Liu 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0019" ref-type="ref">2013</xref>; Li 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0017" ref-type="ref">2017</xref>). For ZIKV, treatment with 25HC protected mice and rhesus monkeys from ZIKV infection (Li 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0017" ref-type="ref">2017</xref>). For the mechanism of entry inhibition, there is evidence that 25HC could modify plasma membrane composition (Liu 
 <italic>et al</italic>, 
 <xref rid="embj2020106057-bib-0019" ref-type="ref">2013</xref>). However, the pathways mediating 25HC‐induced modification of the plasma membrane that inhibits virus entry are unclear.
</p>
